ASX Weekly Roundup — 06 Jul to 10 Jul 2026
Weekly summary of the most significant bullish and bearish ASX announcements for the week of 06 Jul to 10 Jul 2026, focusing on shorted stocks.
It was a week of stark contrasts on the ASX, defined by a heavy sense of finality for some and explosive momentum for others. While the broader market navigated a mixed landscape, the corporate announcements tell a story of two very different worlds: the "exit door" phase for several major players and a high-stakes restructuring saga for the biotech and energy sectors.
Bullish Signals
ASX:CGS — Cogstate Ltd
If you were looking for a growth story to highlight the strength of the clinical trials sector, Cogstate (CGS) just delivered a masterclass. The company’s FY26 business update was nothing short of a powerhouse, headlined by a staggering 116% year-on-year surge in net sales contracts, which hit a record $89.0 million. This isn't just a spike in activity; it is a massive expansion of the company's revenue visibility. With total contracted future revenue sitting at $118.5 million—a 32% increase over last year—the company has essentially built a formidable moat for the upcoming fiscal year.
Crucially, the near-term outlook looks even brighter, with $48.3 million in revenue already slotted for FY27, representing a 54% jump from the previous year. For investors, this provides a level of predictability that is rare in mid-cap growth stocks. What about the bears? With a short interest of just 0.06%, there isn't much "squeeze" potential here, but the sheer scale of the contract backlog makes the short thesis increasingly difficult to defend. As the Clinical Trials division continues to act as the primary growth engine, the momentum seems geared toward sustained capital appreciation rather than speculative volatility.
ASX:MCE — Matrix Composites & Engineering Ltd
The era of Matrix Composites as a listed entity is drawing to a close, and the news is a definitive "green light" for shareholders looking for an exit. In a landslide victory, shareholders approved the acquisition by Advanced Innergy Solutions Australia with a massive 99.8% of total votes cast in favour. This level of consensus effectively removes the last major hurdle for the takeover, with the second court hearing scheduled for 13 July 2026.
While the imminent delisting on 24 July 2026 means the end of the road for speculative trading, the news is fundamentally positive for those seeking liquidity. The certainty provided by this overwhelming vote eliminates the "deal risk" that often plagues takeover schemes. For anyone holding the stock, the focus now shifts to the final settlement and the transition to a wholly-owned subsidiary. It is a rare moment of absolute clarity in a market often clouded by regulatory delays.
ASX:QUB — Qube Holdings Limited
Qube Holdings has finally crossed the finish line in its transition to private ownership. The Supreme Court of NSW has formally approved the Rubik Australia takeover scheme, a pivotal legal milestone that was set in motion back in February. With the scheme set to become effective on 8 July 2026, the company is now entering its final days of public trading before being suspended from the ASX.
This announcement provides the ultimate level of certainty for shareholders, guaranteeing the acquisition terms that have been the subject of market speculation for months. For the very small number of holders currently shorting the stock (1.13%), the window for profit has effectively slammed shut. As the company moves toward delisting, the focus shifts from market movement to the final distribution of value to shareholders.
Bearish Signals
ASX:QPM — QPM Energy Limited
The news out of QPM Energy is, frankly, sobering. The company has entered voluntary administration, with McGrathNicol and FTI Consulting stepping in to manage the fallout. This is a dual-appointment structure that signals deep-seated complexity, with receivers appointed over specific gas-producing subsidiaries. For shareholders, the situation is dire; shares remain suspended, meaning liquidity has evaporated and investors are effectively locked in while administrators attempt to salvage what remains of the group's assets.
The bear case here has shifted from a theory to a structural reality. The appointment of both administrators and receivers suggests a struggle between secured creditors and the company's operational viability. While the goal is to assess restructuring options, the immediate reality for equity holders is a high risk of total loss. With a short interest of 0.15%, the bears aren't necessarily looking for a squeeze here; they are simply watching a slow-motion liquidation.
ASX:CYP — Cynata Therapeutics Limited
Cynata Therapeutics is undergoing a radical, and quite frankly, jarring transformation. In a move that signals a total collapse of their current growth trajectory, the company has announced the redundancy of its entire management team, including the CEO and Managing Director. The company is essentially pivoting from an active, clinical-stage biotech to a "shell" entity focused purely on preserving its intellectual property.
While the company has secured a $600,000 loan to extend its runway into FY27, the fundamental business model has been gutted. By terminating clinical trial agreements and outsourced activities, Cynata is effectively pausing its search for a breakthrough to avoid burning through its remaining $1.5 million in proforma cash. For investors, the company has transitioned from a biotech play to a speculative IP-holding vehicle. The risk of losing operational expertise during this "bare-bones" phase is immense, and the path to meaningful valuation is now entirely dependent on the static value of its patent portfolio.
ASX:ADY — Admiralty Resources NL.
The ASX has once again highlighted the risks of regulatory non-compliance, listing Admiralty Resources among several other entities in its "Long Term Suspended" report. These companies have been suspended for over three months because they have failed to meet basic continuous disclosure requirements, such as lodging annual or half-year accounts.
This is a major red flag for any retail investor. The ASX has issued a strict ultimatum: entities have a one-year window to lodge outstanding reports and a two-year window to prove they can resume trading, or they face permanent delisting. When a company stops communicating with the market, it usually signals that the internal governance has broken down or, more concerningly, that the financial distress is so severe they cannot even produce the paperwork to describe it.
The Week Ahead
As we move into the next week, all eyes will be on the court hearings for MCE and QUB, which will serve as the final procedural steps in their delisting processes. We also need to watch the upcoming meeting of creditors for QPM Energy on 17 July; this will be the first real indication of whether there is any hope for a restructuring or if we are looking at a straight liquidation. Finally, keep a close eye on any further regulatory updates regarding the long-term suspended entities, as the ASX continues its crackdown on non-compliant listings.